SCHEMBL288643

SCHEMBL288643

Cc1c(Cl)ncnc1N1CCc2ncccc21

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 1/20 0.39
HTT P42858 2/20 0.36
EGFR P00533 2/20 0.34
CSF1R P07333 1/20 0.34
PTPN11 Q06124 5/20 0.33
SMN1; SMN2 Q16637 3/20 0.33
KCNQ2 O43526 1/20 0.33
HPGD P15428 3/20 0.33
HSD17B10 Q99714 3/20 0.33
KDM4E B2RXH2 2/20 0.33
MAPT P10636 2/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
RXFP1 Q9HBX9 1/20 0.33
ALDH1A1 P00352 1/20 0.33
RET P07949 1/20 0.32
KIF5B P33176 1/20 0.32
KDR P35968 1/20 0.32
KCNH2 Q12809 2/20 0.32
PIK3CA P42336 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL288511 0.83 TRPV1 (0.38) TRPV1HTTHPGDHSD17B10ALDH1A1
SCHEMBL4502152 0.77 P2RX7 (0.38) TRPV1HTTEGFRCSF1RSMN1; SMN2
SCHEMBL287753 0.72 CYP17A1 (0.41) PTPN11KCNQ2KCNH2
SCHEMBL29651160 0.71 RPS6KA5 (0.46) PTPN11HPGDMAPTNPC1RAB9A
SCHEMBL288068 0.71 GPR119 (0.47)
SCHEMBL759311 0.70 GPR119 (0.41) PTPN11KCNH2
SCHEMBL288817 0.70 GPR119 (0.41) PTPN11KCNH2
SCHEMBL299903 0.69 SSTR4 (0.33) PTPN11KCNH2
SCHEMBL760625 0.69 SSTR4 (0.33) PTPN11KCNH2
SCHEMBL760626 0.69 SSTR4 (0.33) PTPN11KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2427450-A1 GPR 119 MODULATORS Pfizer Inc. (US) 2012-03-14 EP disclosed
EP-2427448-A1 Gpr 119 modulators Pfizer Inc. (US) 2012-03-14 EP disclosed
US-20120052130-A1 GPR 119 MODULATORS PFIZER INC. 2012-03-01 US disclosed
US-20120052130-A1 GPR 119 MODULATORS PFIZER INC. 2012-03-01 US disclosed
US-20120052130-A1 GPR 119 MODULATORS PFIZER INC. 2012-03-01 US disclosed
WO-2010128414-A1 GPR 119 MODULATORS PFIZER INC. (US) 2010-11-11 WO disclosed
WO-2010128414-A1 GPR 119 MODULATORS PFIZER INC. (US) 2010-11-11 WO disclosed
WO-2010128425-A1 GPR 119 MODULATORS PFIZER INC. (US) 2010-11-11 WO disclosed
WO-2010128425-A1 GPR 119 MODULATORS PFIZER INC. (US) 2010-11-11 WO disclosed
US-20100285145-A1 GPR 119 MODULATORS PFIZER INC 2010-11-11 US disclosed
US-20100285145-A1 GPR 119 MODULATORS PFIZER INC 2010-11-11 US disclosed
US-20100285145-A1 GPR 119 MODULATORS PFIZER INC 2010-11-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120052130-A1 GPR 119 MODULATORS GPR119, GPR39, GPR65 TRPV1 340/4885HTT 2918/4885EGFR 1874/4885
US-20100285145-A1 GPR 119 MODULATORS GPR119, GPR65, GPR39 TRPV1 366/4885HTT 2620/4885EGFR 2009/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.